Creyon Bio

Creyon Bio: Driving Visibility for Transformative Biotech Innovation

Position Creyon Bio at the forefront of tissue-specific, RNA-targeted oligonucleotide therapy development through its AI-powered Oligo Engineering Engine
Communicate Company’s revitalized leadership team and refined strategic focus on rare and prevalent diseases
Reinforce the Company’s commitment to advancing breakthrough treatments with the announcement of its global licensing and multi-target research collaboration with Eli Lilly and Company

Led strategic messaging and media training sessions to establish clear, differentiated positioning and prioritize stakeholder communications
Developed and implemented an integrated communications plan anchored by two high-impact news releases
Executed a proactive embargo strategy, securing early media interest with advance outreach, interview opportunities, and tailored Q&A materials
Created comprehensive media assets, including a corporate backgrounder and key message Q&A, to support consistent and effective storytelling
Crafted a cohesive narrative that linked both announcements, sustaining momentum and enabling ongoing media engagement

Positioned Creyon as a category innovator, spotlighting its expert leadership and mission to accelerate safer, faster and less expensive drug development
Secured 40 earned media placements and facilitated 5 executive interviews, significantly raising the Company’s profile across trade and business media
Generated broad media pickup, with news releases featured by 620 outlets and reaching a combined audience of 245.2 million unique visitors per month
Drove strong social engagement with LinkedIn content garnering 224 likes, 53 reposts, and 12 comments, reinforcing visibility and thought leadership among industry stakeholders